This Is the Best Time to Buy These 5 Long-Term Dividend Stocks

2. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 79

Dividend Yield as of November 1: 3.44%

Pfizer Inc. (NYSE:PFE) is a healthcare and pharmaceutical company selling biopharmaceutical products across the globe. The company is based in New York, US.

SVB Securities analyst David Risinger holds a Market Perform rating on Pfizer Inc. (NYSE:PFE), alongside a $48 price target.

The company has raised its dividend yield for the past 12 years consistently, making it a reliable dividend stock in the healthcare sector. Recently, Pfizer Inc. (NYSE:PFE) also raised its 2022 earnings guidance to $34 billion, representing a $2 billion increase from the previous figure. It has also revised its revenue and adjusted EPS guidance to $99.5 billion – $102 billion and $6.4-$6.5, compared to consensus estimates of $99.6 billion and $6.39.

Pfizer Inc. (NYSE:PFE) was found among the 13F holdings of 79 hedge funds in the second quarter and 83 hedge funds in the previous quarter. Their total stake values were $4.1 billion and $5.1 billion, respectively.

Carillon Tower Advisers, an investment management company, mentioned Pfizer Inc. (NYSE:PFE) in its second-quarter 2022 investor letter. Here’s what the firm said:

“Pfizer Inc. (NYSE:PFE) is a research-based global biopharmaceutical company. The United States agreed to pay Pfizer and its vaccine partner more than $3 billion in a deal for their messenger RNA shots against COVID-19. Additionally, the U.S. Food and Drug Administration authorized the company’s COVID vaccine for children aged 5 to 11.”